Sp1139

IMPLEMENTATION OF THE NEW NOMENCLATURE IN RESEARCH AND JOURNAL PUBLICATIONS: THE EPIDEMIOLOGY AND NATURAL HISTORY OF SLD NEW SUB-CLASSIFICATIONS

Date
May 21, 2024

Presenter

Speaker Image for Fasiha Kanwal
Michael E. DeBakey VAMC

Tracks

Related Products

Thumbnail for NAFLD TO MASLD: YEAR IN REVIEW
Thumbnail for HCC RISK ASSESSMENT: ARE CURRENT RECOMMENDATIONS TOO IMPRECISE?
Thumbnail for PAAM FOR HEPATOCELLULAR CARCINOMA RISK STRATIFICATION IN PATIENTS WITH CIRRHOSIS: MULTICENTER PHASE 3 BIOMARKER VALIDATION STUDIES IN THE U.S.
PAAM FOR HEPATOCELLULAR CARCINOMA RISK STRATIFICATION IN PATIENTS WITH CIRRHOSIS: MULTICENTER PHASE 3 BIOMARKER VALIDATION STUDIES IN THE U.S.
BACKGROUND: With the recent increase in metabolic liver diseases and viral hepatitis on anti-viral agents, risk stratification biomarkers are urgently needed to identify cirrhosis patients who should be prioritized for hepatocellular carcinoma (HCC) screening for early detection…
Thumbnail for AASLD Presidential Plenary
AASLD Presidential Plenary
ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)